Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

26.02.2024

1 Am J Surg Pathol
1 Cancer Lett
3 Eur J Obstet Gynecol Reprod Biol
5 Gynecol Oncol



    Am J Surg Pathol

  1. KEYHANIAN K, Han L, Howitt BE, Longacre T, et al
    Specific Pathology Features Enrich Selection of Endometrial Carcinomas for POLE Testing.
    Am J Surg Pathol. 2023 Dec 8. doi: 10.1097/PAS.0000000000002165.
    >> Share


    Cancer Lett

  2. LIU J, Liu C, Ma Y, Pan X, et al
    STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs).
    Cancer Lett. 2024 Feb 17:216700. doi: 10.1016/j.canlet.2024.216700.
    >> Share


    Eur J Obstet Gynecol Reprod Biol

  3. PETIOT F, Descargues P, Devouassoux-Shisheboran M, You B, et al
    Retrospective analysis of uterine involvement in low grade serous ovarian carcinoma.
    Eur J Obstet Gynecol Reprod Biol. 2024;294:191-197.
    >> Share

  4. DABI Y, Rockall A, Razakamanantsoa L, Guerra A, et al
    O-RADS MRI scoring system has the potential to reduce the frequency of avoidable adnexal surgery.
    Eur J Obstet Gynecol Reprod Biol. 2024;294:135-142.
    >> Share

  5. MALIK N, Sahu B
    Counselling and management of women with genetic predisposition to gynaecological cancers.
    Eur J Obstet Gynecol Reprod Biol. 2024;294:44-48.
    >> Share


    Gynecol Oncol

  6. PENFOUND S, Lukey A, Hodgson J, Hopman WM, et al
    Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database.
    Gynecol Oncol. 2024;185:116-120.
    >> Share

  7. SUIDAN RS, Sun CC, Schneider AK, Lu KH, et al
    Determination of quality of life-related health utilities for surgical complications in ovarian cancer.
    Gynecol Oncol. 2024;185:101-107.
    >> Share

  8. DISIPIO T, Hartel G, Butow P, Webb PM, et al
    Impact of disease recurrence on the supportive care needs of patients with ovarian cancer and their caregivers.
    Gynecol Oncol. 2024;185:33-41.
    >> Share

  9. KOSKELA H, Li Y, Joutsiniemi T, Muranen T, et al
    HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
    Gynecol Oncol. 2023;180:91-98.
    >> Share

  10. NASIOUDIS D, Gysler S, Latif N, Cory L, et al
    Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
    Gynecol Oncol. 2023;180:1-5.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016